Du är här

2016-02-16

Biofrontera AG: Biofrontera AG resolves on capital increase

ital increase.
Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is
solely responsible for the content of this announcement.
Leverkusen, Germany, February 16, 2016 - The Management Board of Biofrontera
AG (FSE: B8F) has resolved on 12 February 2016, with the approval of the
Supervisory Board, to increase the registered share capital of the Company by
up to EUR 2,357,384 from authorized capital by issuing up to 2,357,384 new
no-par registered shares ("New Shares"). The shareholders' subscription right
is excluded. The New Shares were offered to selected institutional investors
at an issue price of EUR 1.90 per New Share, for a total issue price of EUR
4,479,029.60. All shares were successfully placed today.

The net proceeds of approx. EUR 4.4 mio will be used to cover the operational
expenses of the Company and the further development of marketing the
Company's main product BF-200 ALA. Currently, BF-200 ALA is approved for the
treatment of actinic keratosis in the EU. With the proceeds from this issue,
the Company intends to support the regulatory approval and commercialization
in the US as well as the extension of the European approval of BF-200 ALA for
treatment of basal cell carcinoma.

About Biofrontera

Biofrontera Group
(FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising
in the development, sale and distribution of drugs and medical cosmetics for
the care and treatment of skin diseases. Biofrontera's most important product
isAmeluz®
, a prescription drug which is approved in Europe for the treatment of mild
and moderate actinic keratosis (superficial skin cancer) with photodynamic
therapy (light therapy). Biofrontera is the first German pharmaceutical
start-up company to obtain centralised approval for a drug it has developed
itself. The company also plans for Ameluz® to be approved for basal cell
carcinoma and is currently preparing for approval in other countries,
especially in the largest pharmaceutical market in the world, the United
States.

The company also markets the Belixos® dermatological range of cosmetics.
Belixos® products, a cream, a gel and a scalp tonic, contain combinations of
active substances extracted from plants, relieve itching and redness and are
used for the regenerative care of chronic skin conditions such as atopic
dermatitis or psoriasis. The Belixos® Protect, a daily skincare for
sun-damaged skin, complements this dermo-cosmetic line. All products are
available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the
Chairman of the company's Management Board, and has its headquarters in
Leverkusen, Germany.

For more information, visitwww.biofrontera.com

This communication expressly or implicitly contains certain forward-looking
statements concerning the business activities of Biofrontera AG. These
forward-looking statements reflect the opinion of Biofrontera at the time of
this communication and involve certain known and unknown risks. The actual
results achieved by Biofrontera may differ significantly from future results
or performances which are published in its forward-looking statements.
Biofrontera assumes no responsibility to update its forward-looking
statements.

U.S. Contact:

The Ruth Group

Lee Roth (Investors) / Kirsten Thomas (Media)
lroth@theruthgroup.com/kthomas@theruthgroup.com

+1 646-536-7012 / +1 508-280-6592

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biofrontera AG via Globenewswire

HUG#1986504

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.